Canada’s Vaping Paradox: Decoding the Data on Lives Saved and Risks Remaining

OTTAWA, ON – August 10, 2026 – In the charged public square of health policy, few topics generate more heat and less light than vaping. It is simultaneously cast as a public health menace hooking a new generation on nicotine and a revolutionary tool for saving smokers from the grave. Now, the Canadian Vaping Association (CVA) is making a bold, data-driven push to reframe the narrative, armed with peer-reviewed research suggesting the legalization of nicotine vaping products (NVPs) is already on track to save over 125,000 Canadian lives.

This claim, rooted in sophisticated modeling, forces a critical question: has the signal of a major public health victory been lost in the noise of a legitimate moral panic? As Canada charts its course toward a smoke-free future, a forensic look at the evidence reveals a complex reality, one where life-saving potential coexists with persistent risks, and where scientific findings clash with the powerful force of public perception.

The Projection and the Proof

At the heart of the CVA's argument is a study published in BMJ Public Health that uses a validated simulation tool, the Canada Smoking and Vaping Model (SAVM). By modeling population trends following the 2018 Tobacco and Vaping Products Act (TVPA) which legalized NVP sales, the researchers projected a staggering public health benefit: the prevention of an estimated 125,300 smoking- and vaping-attributable deaths and the preservation of 2.6 million life-years for Canadians through 2060.

The model works by comparing a scenario where NVPs remained legally inaccessible to the current reality where they are a regulated alternative. The results indicate that the availability of NVPs accelerated the decline in smoking, particularly among young adults, who saw some of the largest reductions in cigarette use. The core mechanism, the study suggests, is smokers switching from deadly combustible tobacco to a significantly less harmful alternative.

This finding is not an isolated event. It echoes a 2025 economic analysis from researchers at the University of Missouri and Yale University, who examined a pivotal 2010 U.S. court decision that exempted e-cigarettes from pharmaceutical regulation. Their analysis concluded this market liberalization saved an estimated 677,000 life-years in the U.S. between 2011 and 2019, primarily by facilitating the switch from smoking. Extrapolated to Canada’s population, this would represent a saving of nearly 42,000 life-years annually.

“When adult smokers have access to regulated vaping products, fewer of them die from smoking-related illnesses,” said Sam Tam, President of the CVA, in a recent statement. “That is what two independent research teams, using two different countries’ data and two different methods, both found.”

However, the researchers behind the SAVM model themselves urge caution. Simulation models, by their nature, depend on assumptions—in this case, about the rates at which smokers switch to vaping and the relative risks of each behavior. While large, independent evidence reviews consistently find vaping to be a fraction of the risk of smoking, the long-term health effects are not fully known. The model's projected benefits represent a trade-off, balancing the immense harm reduction from quitting cigarettes against the lesser, but not zero, risks of initiating or continuing NVP use.

A Tale of Two Trends: Adult Smokers and Youth Vapers

The 2018 TVPA was crafted with a delicate, dual objective: help adult smokers quit while protecting youth from nicotine addiction. The data suggests a split decision. For adult smokers, the strategy appears to be paying dividends. Smoking prevalence has fallen sharply since 2018, a trend the SAVM study attributes in significant part to the availability of a regulated alternative. Approximately one in five Canadians who quit smoking in 2024 reported using an e-cigarette to help them, according to Health Canada.

But the story for youth is more complicated. The CVA points to the 2024 Canadian Health Survey on Children and Youth (CHSCY), which reportedly shows youth vaping has declined nearly 60% from its 2019 peak. While this suggests progress, it's crucial to remember the context of that peak. Following the 2018 legalization and the entry of slick, high-nicotine products into the Canadian market, youth vaping rates surged. Between 2017 and 2018 alone, past-30-day vaping among 16-to-19-year-olds increased by 74%.

This spike triggered widespread concern among pediatric health organizations and fueled the narrative of a new youth epidemic. Public health experts note that while the TVPA restricts youth access on paper, enforcement can be a challenge. One study using “secret shoppers” found that a significant percentage of vendors were willing to sell to young people in improper circumstances. The debate over flavored products, highly popular with youth but also cited by many adults as key to their own transition from smoking, further complicates the regulatory landscape. This tension highlights the immense difficulty in crafting policy that serves two distinct populations with a single product category.

When Evidence Meets Emotion: The Moralization of Vaping

Perhaps the most insightful piece of the puzzle comes not from epidemiology, but from social science. A 2025 study in Addiction Research & Theory offers a compelling explanation for the gap between the harm-reduction evidence and the public’s deep-seated anxiety: “attitude moralization.”

The researchers found that when people come to view vaping as morally wrong—rather than simply risky—they become significantly less willing to trust new scientific evidence about its potential benefits. This cognitive barrier holds firm regardless of the evidence's quality or the person's general trust in science. Once a behavior is framed as a moral failing, data that contradicts that frame is often dismissed out of hand.

“It’s not that the science is weak or contested, it’s that vaping has become a moral issue in Canada, and that changes how people process new information,” Tam noted. This moralization is often fueled by the perceived harm to a vulnerable group—in this case, children. The narrative of predatory companies hooking kids on nicotine is powerful and emotionally resonant, and it can easily overshadow complex statistical arguments about population-level health gains among adults.

This phenomenon presents a profound challenge for public health communication. If a significant portion of the public and policymakers are filtering scientific data through a moral lens, then simply presenting more data may not be enough to shift the conversation. It suggests the path forward requires not only rigorous science but also a deeper understanding of the social and psychological forces that shape our response to it.

As the data continues to accumulate, the challenge for policymakers and the public alike will be to navigate a landscape shaped as much by statistical models as by deeply held moral convictions.